Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Matinas Biopharma Holdings, Inc. (OTC: MTNB).

Full DD Report for MTNB

You must become a subscriber to view this report.


Recent News from (OTC: MTNB)

Matinas Biopharma Holdings' (MTNB) CEO Jerry Jabbour on Q1 2018 Results - Earnings Call Transcript
Matinas Biopharma Holdings (MTNB) Q1 2018 Earnings Conference Call May 10, 2018 08:30 AM ET Executives Jenene Thomas - IR Jerry Jabbour - CEO Raphael Mannino - CSO Analysts Jason McCarthy - Maxim Group Julian Harrison - H.C. Wainwright Presentation Operator Gree...
Source: SeekingAlpha
Date: May, 13 2018 14:21
Matinas Biopharma Holdings misses by $0.01
Matinas Biopharma Holdings (NYSEMKT: MTNB ): Q1 EPS of -$0.05 misses by $0.01 . More news on: Matinas Biopharma Holdings, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 10 2018 07:08
Matinas BioPharma Reports First Quarter 2018 Financial Results and Provides Corporate Update
– Management to host conference call with live audio webcast today, Thursday, May 10 th at 8:30 am EDT – BEDMINSTER, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on enabling...
Source: GlobeNewswire
Date: May, 10 2018 07:05
Matinas BioPharma Selected to Present at the BioNJ Eighth Annual BioPartnering Conference
BEDMINSTER, N.J., May 01, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative medicines using its proprietary lipid nano-crystal (“LNC”) platform delivery technology, today an...
Source: GlobeNewswire
Date: May, 01 2018 08:05
Matinas BioPharma to Present Positive Preclinical Data of MAT2203 at the 28th European Congress of Clinical Microbiology and Infectious Disease
BEDMINSTER, N.J., April 19, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced that it will present a poster at the 28 th European...
Source: GlobeNewswire
Date: April, 19 2018 08:05
Matinas BioPharma Reports 2017 Financial Results
BEDMINSTER, N.J., March 26, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today formally announced its financial results for the year ended Dec...
Source: GlobeNewswire
Date: March, 26 2018 16:45
Matinas Biopharma Holdings' (MTNB) CEO Jerome Jabbour on Q4 2017 Results - Earnings Call Transcript
Matinas Biopharma Holdings, Inc. (MTNB) Q4 2017 Earnings Conference Call March 19, 2018 8:30 AM ET Executives Jenene Thomas - Chief Executive Officer and Founder, Jenene Thomas Communications, LLC Jerome Jabbour - Chief Executive Officer Matthew Wikler - Member of Board of Direct...
Source: SeekingAlpha
Date: March, 19 2018 14:11
Matinas BioPharma Appoints Jerome D. Jabbour as Chief Executive Officer and Provides Corporate Update
Leadership appointment positions Company for next stage of value creation Successful outcome of meeting with FDA provided important insight and clarity for clinical development path forward for MAT2203 Conference call and live audio webcast to be held on March 19 th at 8:30 a.m. ET...
Source: GlobeNewswire
Date: March, 16 2018 17:00
Key events next week - healthcare (continued #1)
Tuesday (3/20): Oppenheimer (continued). BioLineRx (NASDAQ: BLRX ); Aerie Pharmaceuticals (NASDAQ: AERI ); United Therapeutics (NASDAQ: UTHR ); Addus HomeCare (NASDAQ: ADUS ); Centene (NYSE: CNC ); Quorum Health (NYSE: QHC ); Pfenex (NYSEMKT: PFNX ); SELLAS Life Sciences (NASDAQ: SLS...
Source: SeekingAlpha
Date: March, 16 2018 10:26
Matinas BioPharma to Present at the Oppenheimer 28th Annual Healthcare Conference
BEDMINSTER, N.J., March 15, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, today announced that Co-Founder and President, Jerome D. Jabbour, will...
Source: GlobeNewswire
Date: March, 15 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-210.41650.410.450.398229,607
2018-08-200.380.39650.41990.372223,448
2018-08-170.390.3650.400.365167,501
2018-08-160.38790.38010.38790.3634,672
2018-08-150.370.38350.38790.361123,650

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2017-03-01152,638252,34860.4871Short
2017-02-2882,355167,09049.2878Short
2017-02-2793,512219,31842.6376Short
2017-02-2450,36781,42461.8577Short
2017-02-23117,815245,10948.0664Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MTNB.


About Matinas Biopharma Holdings, Inc. (OTC: MTNB)

Logo for Matinas Biopharma Holdings, Inc. (OTC: MTNB)

Matinas BioPharma is a clinical stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life threatening infections. The Company s proprietary, disruptive technology utilizes lipid crystal nano particle cochleates to nano encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. The Company s lead drug candidate is MAT , an orally administered, encochleated formulation of amphotericin B a broad spectrum fungicidal agent . The Company has an open Investigational New Drug IND application for MAT , which is an orally administered, encochleated formulation of amikacin a broad spectrum aminoglycoside antibiotic agent for acute bacterial infections, including non tuberculous mycobacterium NTM and multi drug resistant gram negative bacterial infections. For more information, please visit www.matinasbiopharma.com lt / td gt

 

 

 

Current Management

  • Roelof Rongen / CEO
  • Jerry Jabbour / President, General Counsel, EVP
  • Gary Gaglione / Interim CFO
  • Abdel Fawzy / EVP, Bus. Affairs
  • Douglas F. Kling / Senior VP
  • Raphael J. Mannino / CSO, CTO
  • Herbert Conrad / Chairman
  • Stefano Ferrari /
  • Roelof Rongen /
  • James Scibetta /
  • Adam Stern /

Current Share Structure

  • Market Cap: $97,217,746 - 03/09/2018
  • Authorized: 250,000,000 - 03/01/2018
  • Issue and Outstanding: 93,478,602 - 03/01/2018
  • Float: 31,187,778 - 01/20/2017

 


Recent Filings from (OTC: MTNB)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 27 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 16 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: February, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 14 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 14 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 26 2017
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: September, 14 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 10 2017

 

 


Daily Technical Chart for (OTC: MTNB)

Daily Technical Chart for (OTC: MTNB)


Stay tuned for daily updates and more on (OTC: MTNB)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: MTNB)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MTNB is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of MTNB and does not buy, sell, or trade any shares of MTNB. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/